204 related articles for article (PubMed ID: 12588776)
21. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
Chan DC; Wong AT; Yamashita S; Watts GF
Atherosclerosis; 2012 Apr; 221(2):484-9. PubMed ID: 22341868
[TBL] [Abstract][Full Text] [Related]
22. Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol.
Lewis TV; Dart AM; Chin-Dusting JP
J Am Coll Cardiol; 1999 Mar; 33(3):805-12. PubMed ID: 10080485
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans.
Watanabe S; Tagawa T; Yamakawa K; Shimabukuro M; Ueda S
Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2376-80. PubMed ID: 16179595
[TBL] [Abstract][Full Text] [Related]
24. Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized, placebo-controlled study.
Duffy SJ; O'Brien RC; New G; Harper RW; Meredith IT
Clin Exp Pharmacol Physiol; 2001; 28(5-6):409-18. PubMed ID: 11380515
[TBL] [Abstract][Full Text] [Related]
25. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia.
Jonkers IJ; de Man FH; van der Laarse A; Frölich M; Gevers Leuven JA; Kamper AM; Blauw GJ; Smelt AH
J Hypertens; 2001 Apr; 19(4):749-55. PubMed ID: 11330878
[TBL] [Abstract][Full Text] [Related]
26. Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia.
Esenboga K; Çiçek ÖF; Oktay AA; Ayral PA; Gürlek A
Adv Clin Exp Med; 2019 Jul; 28(7):931-936. PubMed ID: 31237119
[TBL] [Abstract][Full Text] [Related]
27. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity.
Chowienczyk PJ; Watts GF; Wierzbicki AS; Cockcroft JR; Brett SE; Ritter JM
J Am Coll Cardiol; 1997 Apr; 29(5):964-8. PubMed ID: 9120182
[TBL] [Abstract][Full Text] [Related]
28. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
Bays HE; Hallén J; Vige R; Fraser D; Zhou R; Hustvedt SO; Orloff DG; Kastelein JJ
J Clin Lipidol; 2016; 10(1):181-91.e1-2. PubMed ID: 26892135
[TBL] [Abstract][Full Text] [Related]
29. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition.
de Kreutzenberg SV; Crepaldi C; Marchetto S; Calò L; Tiengo A; Del Prato S; Avogaro A
J Clin Endocrinol Metab; 2000 Feb; 85(2):793-8. PubMed ID: 10690892
[TBL] [Abstract][Full Text] [Related]
30. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations.
Jeng CY; Sheu WH; Fuh MM; Shieh SM; Chen YD; Reaven GM
J Clin Endocrinol Metab; 1996 Jul; 81(7):2550-3. PubMed ID: 8675576
[TBL] [Abstract][Full Text] [Related]
31. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
[TBL] [Abstract][Full Text] [Related]
32. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
[TBL] [Abstract][Full Text] [Related]
33. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia.
Rivellese AA; Maffettone A; Iovine C; Di Marino L; Annuzzi G; Mancini M; Riccardi G
Diabetes Care; 1996 Nov; 19(11):1207-13. PubMed ID: 8908381
[TBL] [Abstract][Full Text] [Related]
35. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
36. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults.
Walker AE; Kaplon RE; Lucking SM; Russell-Nowlan MJ; Eckel RH; Seals DR
Hypertension; 2012 Dec; 60(6):1517-23. PubMed ID: 23108655
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
[TBL] [Abstract][Full Text] [Related]
38. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
39. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
Wysocki J; Belowski D; Kalina M; Kochanski L; Okopien B; Kalina Z
Int J Clin Pharmacol Ther; 2004 Apr; 42(4):212-7. PubMed ID: 15124979
[TBL] [Abstract][Full Text] [Related]
40. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin.
de Man FH; Weverling-Rijnsburger AW; van der Laarse A; Smelt AH; Jukema JW; Blauw GJ
Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):744-50. PubMed ID: 10712400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
